Market News AIOpen the app

NuCana showed new research that its drug NUC-7738 makes carfilzomib work better against cancer cells.

TrialRead the original at globenewswire.com
Good for NCNA

NuCana said NUC-7738 strengthened carfilzomib's effect, and the pair showed activity in 28 of 33 lab tumor models. These early findings support more study, but do not show whether patients will benefit.

NCNA · NuCana plc

AI read · Good for NCNA

The AI's read

The stronger blocking of a cancer-cell process gives NuCana a possible new use for NUC-7738. The lab work points to cancers beyond multiple myeloma. But lab results do not show that the combination helps people. NuCana plans to share final results from its NUC-7738 and pembrolizumab study in December 2026.

Get alerts for NCNA

Follow NuCana plc (NCNA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NCNA
Free on the App Store and Google Play, or on the web.